{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:28:51Z","timestamp":1791822531815,"version":"4.3.4"},"reference-count":106,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1097\/tp.0000000000000777","type":"journal-article","created":{"date-parts":[[2015,6,4]],"date-time":"2015-06-04T08:47:57Z","timestamp":1433407677000},"page":"1321-1334","source":"Crossref","is-referenced-by-count":56,"title":["Rational Basis for Optimizing Short and Long-term Hepatitis B Virus Prophylaxis Post Liver Transplantation"],"prefix":"10.1097","volume":"99","author":[{"given":"Bruno","family":"Roche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Marie","family":"Roque-Afonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Nevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20210129","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.jhep.2011.08.026","article-title":"The option of HBIG-free prophylaxis against recurrent HBV.","volume":"56","author":"Fox","year":"2012","journal-title":"J Hepatol"},{"key":"R2-10-20210129","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/j.1478-3231.2009.02085.x","article-title":"Current management of hepatitis B virus infection before and after liver transplantation.","volume":"29","author":"Papatheodoridis","year":"2009","journal-title":"Liver Int"},{"key":"R3-10-20210129","doi-asserted-by":"crossref","first-page":"14142","DOI":"10.3748\/wjg.v20.i39.14142","article-title":"Hepatitis B and liver transplantation: molecular and clinical features that influence recurrence and outcome.","volume":"20","author":"Ghaziani","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R4-10-20210129","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/jhep.2001.26512","article-title":"Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort.","volume":"34","author":"Yao","year":"2001","journal-title":"Hepatology"},{"key":"R5-10-20210129","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1053\/jhep.2001.21554","article-title":"A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.","volume":"33","author":"Perrillo","year":"2001","journal-title":"Hepatology"},{"key":"R6-10-20210129","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/lt.20981","article-title":"Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results.","volume":"13","author":"Schiff","year":"2007","journal-title":"Liver Transpl"},{"key":"R7-10-20210129","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/hep.24361","article-title":"Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study.","volume":"54","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"key":"R8-10-20210129","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/hep.23952","article-title":"Tenofovir disoproxil fumarate (TDF), emtricitabineTDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.","volume":"53","author":"Liaw","year":"2011","journal-title":"Hepatology"},{"key":"R9-10-20210129","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jhep.2009.11.007","article-title":"Efficacy of entecavir in treatment-naive patients with hepatitis B virus-related decompensated cirrhosis.","volume":"52","author":"Shim","year":"2010","journal-title":"J Hepatol"},{"key":"R10-10-20210129","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1053\/gast.2002.35352","article-title":"Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy.","volume":"123","author":"Fontana","year":"2002","journal-title":"Gastroenterology"},{"key":"R11-10-20210129","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/hep.510310130","article-title":"Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B.","volume":"31","author":"Villeneuve","year":"2000","journal-title":"Hepatology"},{"key":"R12-10-20210129","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1053\/j.gastro.2009.07.047","article-title":"Trends in waiting list registration for liver transplantation for viral hepatitis in the United States.","volume":"137","author":"Kim","year":"2009","journal-title":"Gastroenterology"},{"key":"R13-10-20210129","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jhep.2008.10.001","article-title":"EASL Clinical Practice Guidelines: management of chronic hepatitis B.","volume":"50","author":"European Association For The Study Of The","year":"2009","journal-title":"J Hepatol"},{"key":"R14-10-20210129","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/hep.23190","article-title":"Chronic hepatitis B: update 2009.","volume":"50","author":"Lok","year":"2009","journal-title":"Hepatology"},{"key":"R15-10-20210129","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1111\/j.1600-6143.2010.03046.x","article-title":"Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantation.","volume":"10","author":"Degertekin","year":"2010","journal-title":"Am J Transplant"},{"key":"R16-10-20210129","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1016\/j.transproceed.2010.07.011","article-title":"Outcomes of long-term administration of intravenous hepatitis B immunoglobulins for the prevention of recurrent hepatitis B after liver transplantation.","volume":"42","author":"Pauwelyn","year":"2010","journal-title":"Transplant Proc"},{"key":"R17-10-20210129","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1053\/jhep.2003.50294","article-title":"HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis.","volume":"38","author":"Roche","year":"2003","journal-title":"Hepatology"},{"key":"R18-10-20210129","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/lt.21179","article-title":"Presence of intrahepatic (total and ccc) HBV DNA is not predictive of HBV recurrence after liver transplantation.","volume":"13","author":"Hussain","year":"2007","journal-title":"Liver Transpl"},{"key":"R19-10-20210129","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/TP.0b013e31816a342a","article-title":"Viral persistence after liver transplantation for hepatitis B virus: a cross-sectional study.","volume":"85","author":"Freshwater","year":"2008","journal-title":"Transplantation"},{"key":"R20-10-20210129","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1007\/s12072-011-9265-z","article-title":"Serum hepatitis B virus DNA before liver transplantation correlates with HBV reinfection rate even under successful low-dose hepatitis B immunoglobulin prophylaxis.","volume":"5","author":"Yasunaka","year":"2011","journal-title":"Hepatol Int"},{"key":"R21-10-20210129","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/lt.22312","article-title":"Hepatitis B virus quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy.","volume":"17","author":"Coffin","year":"2011","journal-title":"Liver Transpl"},{"key":"R22-10-20210129","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/lt.22169","article-title":"Occult hepatitis B virus infection of donor and recipient origin after liver transplantation despite nucleoside analogue prophylaxis.","volume":"16","author":"Cheung","year":"2010","journal-title":"Liver Transpl"},{"key":"R23-10-20210129","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.jhep.2010.12.036","article-title":"Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence.","volume":"55","author":"Lenci","year":"2011","journal-title":"J Hepatol"},{"key":"R24-10-20210129","doi-asserted-by":"crossref","first-page":"e00049","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus.","volume":"1","author":"Yan","year":"2012","journal-title":"Elife"},{"key":"R25-10-20210129","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jhep.2010.10.019","article-title":"N-terminal myristoylation-dependent masking of neutralizing epitopes in the preS1 attachment site of hepatitis B virus.","volume":"55","author":"Bremer","year":"2011","journal-title":"J Hepatol"},{"key":"R26-10-20210129","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/hep.26211","article-title":"Hepatitis B virus hepatotropism is mediated by specific receptor recognition in the liver and not restricted to susceptible hosts.","volume":"58","author":"Schieck","year":"2013","journal-title":"Hepatology"},{"key":"R27-10-20210129","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0168-8278(97)80035-9","article-title":"Evidence for selection of hepatitis B mutants after liver transplantation through peripheral blood mononuclear cell infection.","volume":"26","author":"Brind","year":"1997","journal-title":"J Hepatol"},{"key":"R28-10-20210129","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/lt.20402","article-title":"Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence.","volume":"11","author":"Marzano","year":"2005","journal-title":"Liver Transpl"},{"key":"R29-10-20210129","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/lt.20701","article-title":"Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis.","volume":"12","author":"Zheng","year":"2006","journal-title":"Liver Transpl"},{"key":"R30-10-20210129","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1056\/NEJM199312163292503","article-title":"Liver transplantation in European patients with the hepatitis B surface antigen.","volume":"329","author":"Samuel","year":"1993","journal-title":"N Engl J Med"},{"key":"R31-10-20210129","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1002\/lt.20277","article-title":"Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade.","volume":"10","author":"Neff","year":"2004","journal-title":"Liver Transpl"},{"key":"R32-10-20210129","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0168-8278(99)80204-9","article-title":"High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation.","volume":"30","author":"Mutimer","year":"1999","journal-title":"J Hepatol"},{"key":"R34-10-20210129","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/lt.21043","article-title":"Recurrence of hepatitis B is associated with cumulative corticosteroid dose and chemotherapy against hepatocellular carcinoma recurrence after liver transplantation.","volume":"13","author":"Yi","year":"2007","journal-title":"Liver Transpl"},{"key":"R35-10-20210129","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1111\/j.1600-6143.2010.03162.x","article-title":"High viremia, prolonged Lamivudine therapy and recurrent hepatocellular carcinoma predict posttransplant hepatitis B recurrence.","volume":"10","author":"Chun","year":"2010","journal-title":"Am J Transplant"},{"key":"R36-10-20210129","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1002\/lt.21882","article-title":"Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation.","volume":"15","author":"Saab","year":"2009","journal-title":"Liver Transpl"},{"issue":"Suppl 8","key":"R37-10-20210129","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1097\/01.tp.0000446278.43804.f9","article-title":"Section 14. Combination of entecavir plus low-dose on-demand hepatitis B immunoglobulin is effective with very low hepatitis B recurrence after liver transplantation.","volume":"97","author":"Hu","year":"2014","journal-title":"Transplantation"},{"key":"R38-10-20210129","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1016\/S0140-6736(96)04444-3","article-title":"Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis.","volume":"348","author":"Grellier","year":"1996","journal-title":"Lancet"},{"key":"R39-10-20210129","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/00000658-200102000-00018","article-title":"Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis.","volume":"233","author":"Lo","year":"2001","journal-title":"Ann Surg"},{"key":"R40-10-20210129","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1097\/00007890-200004150-00033","article-title":"Lamivudine for hepatitis B in liver transplantation: a single-center experience.","volume":"69","author":"Malkan","year":"2000","journal-title":"Transplantation"},{"key":"R41-10-20210129","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1097\/00007890-200009150-00018","article-title":"Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up.","volume":"70","author":"Mutimer","year":"2000","journal-title":"Transplantation"},{"key":"R42-10-20210129","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/TP.0b013e3181f09c89","article-title":"Prevention and risk factors of the HBV recurrence after orthotopic liver transplantation: 160 cases follow-up study.","volume":"90","author":"Xie","year":"2010","journal-title":"Transplantation"},{"key":"R43-10-20210129","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1053\/j.gastro.2011.06.083","article-title":"Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation.","volume":"141","author":"Fung","year":"2011","journal-title":"Gastroenterology"},{"key":"R44-10-20210129","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1055\/s-0033-1345717","article-title":"The molecular virology of hepatitis B virus.","volume":"33","author":"Glebe","year":"2013","journal-title":"Semin Liver Dis"},{"key":"R45-10-20210129","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/hep.510270133","article-title":"Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis.","volume":"27","author":"Ghany","year":"1998","journal-title":"Hepatology"},{"key":"R46-10-20210129","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/hep.510280237","article-title":"Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin.","volume":"28","author":"Terrault","year":"1998","journal-title":"Hepatology"},{"key":"R47-10-20210129","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1053\/gast.2002.31015","article-title":"Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation.","volume":"122","author":"Bock","year":"2002","journal-title":"Gastroenterology"},{"key":"R48-10-20210129","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1002\/hep.510240601","article-title":"Prophylaxis in liver transplant recipients using a fixed dosing schedule of hepatitis B immunoglobulin.","volume":"24","author":"Terrault","year":"1996","journal-title":"Hepatology"},{"key":"R49-10-20210129","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/0168-8278(91)90869-D","article-title":"Liver transplantation in HBs antigen (HBsAg) carriers. Prevention of hepatitis B virus (HBV) recurrence by passive immunization.","volume":"13","author":"Muller","year":"1991","journal-title":"J Hepatol"},{"key":"R50-10-20210129","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/lt.22226","article-title":"Posttransplantation prophylaxis with primary high-dose hepatitis B immunoglobulin monotherapy and complementary preemptive antiviral add-on.","volume":"17","author":"Hwang","year":"2011","journal-title":"Liver Transpl"},{"key":"R51-10-20210129","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1053\/jhep.2000.19789","article-title":"Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review.","volume":"32","author":"Shouval","year":"2000","journal-title":"Hepatology"},{"key":"R52-10-20210129","doi-asserted-by":"crossref","first-page":"8882","DOI":"10.1128\/JVI.77.16.8882-8892.2003","article-title":"Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions.","volume":"77","author":"Schilling","year":"2003","journal-title":"J Virol"},{"key":"R53-10-20210129","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/hepr.12368","article-title":"Safe and cost-effective control of post-transplantation recurrence of hepatitis B.","volume":"45","author":"Takaki","year":"2015","journal-title":"Hepatol Res"},{"key":"R54-10-20210129","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1097\/00007890-199605150-00013","article-title":"Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization.","volume":"61","author":"McGory","year":"1996","journal-title":"Transplantation"},{"key":"R55-10-20210129","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1002\/lt.22354","article-title":"Hepatitis B immunoglobulin andor nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review.","volume":"17","author":"Cholongitas","year":"2011","journal-title":"Liver Transpl"},{"key":"R56-10-20210129","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.jhep.2006.11.022","article-title":"HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration.","volume":"46","author":"Rosenau","year":"2007","journal-title":"J Hepatol"},{"key":"R57-10-20210129","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/hep.510280241","article-title":"Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin.","volume":"28","author":"Markowitz","year":"1998","journal-title":"Hepatology"},{"key":"R58-10-20210129","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0168-8278(01)00080-0","article-title":"Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis.","volume":"34","author":"Marzano","year":"2001","journal-title":"J Hepatol"},{"key":"R59-10-20210129","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0168-8278(01)00089-7","article-title":"Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection.","volume":"34","author":"Rosenau","year":"2001","journal-title":"J Hepatol"},{"key":"R60-10-20210129","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1053\/jhep.2002.33681","article-title":"Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease.","volume":"35","author":"Steinmuller","year":"2002","journal-title":"Hepatology"},{"key":"R61-10-20210129","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1053\/jlts.2000.18702","article-title":"An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy.","volume":"6","author":"Han","year":"2000","journal-title":"Liver Transpl"},{"key":"R62-10-20210129","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/jmv.21324","article-title":"Role of long-term lamivudine treatment of hepatitis B virus recurrence after liver transplantation.","volume":"80","author":"Woo","year":"2008","journal-title":"J Med Virol"},{"key":"R63-10-20210129","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1053\/j.gastro.2007.01.005","article-title":"Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation.","volume":"132","author":"Gane","year":"2007","journal-title":"Gastroenterology"},{"key":"R65-10-20210129","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1751-2980.2009.00403.x","article-title":"The role of entecavir in preventing hepatitis B recurrence after liver transplantation.","volume":"10","author":"Xi","year":"2009","journal-title":"J Dig Dis"},{"issue":"8","key":"R66-10-20210129","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1111\/j.1600-6143.2010.03208.x","article-title":"Prophylaxis against hepatitis B recurrence posttransplantation using lamivudine and individualized low-dose hepatitis B immunoglobulin.","volume":"10","author":"Jiang","year":"2010","journal-title":"Am J Transplant"},{"key":"R67-10-20210129","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1111\/j.1440-1746.2006.04609.x","article-title":"Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis.","volume":"22","author":"Akyildiz","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"R68-10-20210129","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1399-0012.2011.01448.x","article-title":"Clinical study on prevention of HBV re-infection by entecavir after liver transplantation.","volume":"26","author":"Cai","year":"2012","journal-title":"Clin Transplant"},{"key":"R69-10-20210129","first-page":"383","article-title":"Costs and efficacy of on demand low-dose immunoprophylaxis in HBV transplanted patients: experience in the Romanian program of liver transplantation.","volume":"17","author":"Iacob","year":"2008","journal-title":"J Gastrointestin Liver Dis"},{"key":"R70-10-20210129","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1600-6143.2012.04319.x","article-title":"Safety and efficacy of subcutaneous hepatitis B immunoglobulin after liver transplantation: an open single-arm prospective study.","volume":"13","author":"Di Costanzo","year":"2013","journal-title":"Am J Transplant"},{"key":"R71-10-20210129","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/lt.20582","article-title":"Protective antibody levels and dose requirements for IV 5 Nabi Hepatitis B immune globulin combined with lamivudine in liver transplantation for hepatitis B-induced end stage liver disease.","volume":"12","author":"Dickson","year":"2006","journal-title":"Liver Transpl"},{"key":"R72-10-20210129","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1097\/01.TP.0000118904.63669.EB","article-title":"Low-dose hepatitis B immunoglobulin given on demand in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation.","volume":"77","author":"Di Paolo","year":"2004","journal-title":"Transplantation"},{"key":"R73-10-20210129","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S1665-2681(19)31656-4","article-title":"Efficacy of maintenance subcutaneous hepatitis B immune globulin (HBIG) post-transplant for prophylaxis against hepatitis B recurrence.","volume":"9","author":"Singham","year":"2011","journal-title":"Ann Hepatol"},{"key":"R74-10-20210129","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1432-2277.2011.01222.x","article-title":"Efficacy and safety of subcutaneous human HBV-immunoglobulin (Zutectra) in liver transplantation: an open, prospective, single-arm phase III study.","volume":"24","author":"Yahyazadeh","year":"2011","journal-title":"Transpl Int"},{"key":"R75-10-20210129","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1002\/lt.21343","article-title":"Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation.","volume":"14","author":"Hooman","year":"2008","journal-title":"Liver Transpl"},{"key":"R76-10-20210129","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.cgh.2008.02.055","article-title":"Hepatitis B immunoglobulin and Lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis.","volume":"6","author":"Loomba","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R77-10-20210129","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1432-2277.2008.00784.x","article-title":"Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis.","volume":"22","author":"Rao","year":"2009","journal-title":"Transpl Int"},{"key":"R78-10-20210129","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1399-3062.2009.00470.x","article-title":"Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both Systematic review and meta-analysis.","volume":"12","author":"Katz","year":"2009","journal-title":"Transpl Infect Dis"},{"key":"R79-10-20210129","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1600-6143.2012.04315.x","article-title":"High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis b virus recurrence after liver transplantation: a systematic review.","volume":"13","author":"Cholongitas","year":"2013","journal-title":"Am J Transplant"},{"key":"R80-10-20210129","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1016\/j.transproceed.2010.05.127","article-title":"Efficacy and safety of entecavir andor tenofovir for prophylaxis and treatment of hepatitis B recurrence post-liver transplant.","volume":"42","author":"Jimenez-Perez","year":"2010","journal-title":"Transplant Proc"},{"key":"R81-10-20210129","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/lt.23690","article-title":"Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B.","volume":"19","author":"Perrillo","year":"2013","journal-title":"Liver Transpl"},{"key":"R82-10-20210129","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1002\/hep.510310233","article-title":"Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: a new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation.","volume":"31","author":"Sanchez-Fueyo","year":"2000","journal-title":"Hepatology"},{"key":"R83-10-20210129","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1053\/jhep.2002.30278","article-title":"Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis.","volume":"35","author":"Angelico","year":"2002","journal-title":"Hepatology"},{"key":"R84-10-20210129","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/hep.1840380407","article-title":"Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease.","volume":"38","author":"Bienzle","year":"2003","journal-title":"Hepatology"},{"key":"R85-10-20210129","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/S0041-1345(03)00633-X","article-title":"Prophylaxis of recurrent hepatitis B virus by vaccination after liver transplant: preliminary results.","volume":"35","author":"Albeniz Arbizu","year":"2003","journal-title":"Transplant Proc"},{"key":"R86-10-20210129","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jhep.2005.03.013","article-title":"Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B.","volume":"43","author":"Lo","year":"2005","journal-title":"J Hepatol"},{"key":"R87-10-20210129","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/lt.21003","article-title":"Failure of hepatitis B vaccination with conventional HBsAg vaccine in patients with continuous HBIG prophylaxis after liver transplantation.","volume":"13","author":"Rosenau","year":"2007","journal-title":"Liver Transpl"},{"key":"R88-10-20210129","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s10620-009-0999-6","article-title":"HBIg discontinuation with maintenance oral anti-viral therapy and HBV vaccination in liver transplant recipients.","volume":"55","author":"Weber","year":"2010","journal-title":"Dig Dis Sci"},{"key":"R89-10-20210129","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/j.1432-2277.2010.01104.x","article-title":"One-year vaccination against hepatitis B virus with a MPL-vaccine in liver transplant patients for HBV-related cirrhosis.","volume":"23","author":"Di Paolo","year":"2010","journal-title":"Transpl Int"},{"key":"R90-10-20210129","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/lt.20674","article-title":"Immunization with an adjuvant hepatitis B vaccine in liver transplant recipients: antibody decline and booster vaccination with conventional vaccine.","volume":"12","author":"Gunther","year":"2006","journal-title":"Liver Transpl"},{"key":"R91-10-20210129","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1053\/jlts.2000.6446","article-title":"Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation.","volume":"6","author":"Dodson","year":"2000","journal-title":"Liver Transpl"},{"key":"R92-10-20210129","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S0168-8278(01)00039-3","article-title":"Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation.","volume":"34","author":"Naoumov","year":"2001","journal-title":"J Hepatol"},{"key":"R93-10-20210129","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0168-8278(03)00087-4","article-title":"A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation.","volume":"38","author":"Buti","year":"2003","journal-title":"J Hepatol"},{"key":"R94-10-20210129","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1097\/01.tp.0000277289.23677.0a","article-title":"Adherence to Lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence.","volume":"84","author":"Buti","year":"2007","journal-title":"Transplantation"},{"key":"R95-10-20210129","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/lt.21041","article-title":"Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy.","volume":"13","author":"Wong","year":"2007","journal-title":"Liver Transpl"},{"key":"R96-10-20210129","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1007\/s10620-006-9658-3","article-title":"Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin.","volume":"52","author":"Neff","year":"2007","journal-title":"Dig Dis Sci"},{"key":"R97-10-20210129","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1002\/hep.22524","article-title":"A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis.","volume":"48","author":"Angus","year":"2008","journal-title":"Hepatology"},{"key":"R98-10-20210129","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1600-6143.2010.03416.x","article-title":"Posttransplantation hepatitis B prophylaxis with combination oral nucleoside and nucleotide analog therapy.","volume":"11","author":"Saab","year":"2011","journal-title":"Am J Transplant"},{"key":"R99-10-20210129","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1002\/lt.23628","article-title":"Randomized trial of emtricitabinetenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation.","volume":"19","author":"Teperman","year":"2013","journal-title":"Liver Transpl"},{"key":"R100-10-20210129","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/lt.23600","article-title":"Combination lamivudine plus adefovir without HBIG is safe and effective prophylaxis against HBV recurrence in HBsAg liver transplant candidates.","volume":"19","author":"Gane","year":"2013","journal-title":"Liver Transpl"},{"key":"R101-10-20210129","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1399-0012.2005.00467.x","article-title":"Hepatitis B prophylaxis post-liver transplant without maintenance hepatitis B immunoglobulin therapy.","volume":"20","author":"Nath","year":"2006","journal-title":"Clin Transplant"},{"key":"R102-10-20210129","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1007\/s00535-013-0761-x","article-title":"Post-transplantation sequential entecavir monotherapy following 1-year combination therapy with hepatitis B immunoglobulin.","volume":"48","author":"Yi","year":"2013","journal-title":"J Gastroenterol"},{"key":"R103-10-20210129","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1155\/2014\/839014","article-title":"One year of hepatitis B immunoglobulin plus tenofovir therapy is safe and effective in preventing recurrent hepatitis B post-liver transplantation.","volume":"28","author":"Tanaka","year":"2014","journal-title":"Can J Gastroenterol Hepatol"},{"key":"R104-10-20210129","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/lt.21712","article-title":"Decision analysis model for hepatitis B prophylaxis one year after liver transplantation.","volume":"15","author":"Saab","year":"2009","journal-title":"Liver Transpl"},{"key":"R105-10-20210129","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/ajg.2013.111","article-title":"Oral nucleosidenucleotide analogs without hepatitis B immune globulin after liver transplantation for hepatitis B.","volume":"108","author":"Fung","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"R106-10-20210129","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1002\/lt.20416","article-title":"Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine.","volume":"11","author":"Lo","year":"2005","journal-title":"Liver Transpl"},{"key":"R107-10-20210129","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1399-0012.2006.00557.x","article-title":"Lamivudine monoprophylaxis for liver transplant recipients with non-replicating hepatitis B virus infection.","volume":"21","author":"Yoshida","year":"2007","journal-title":"Clin Transplant"},{"key":"R108-10-20210129","first-page":"38","article-title":"Living related liver transplant (LRLT) in HBV DNA negative cirrhosis without hepatitis B immune globulin (HBIG).","volume":"5","author":"Wadhawan","year":"2011","journal-title":"Hepatol Int"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TP.0000000000000777","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T09:33:40Z","timestamp":1748424820000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007890-201507000-00010"}},"subtitle":["Role of Hepatitis B Immune Globulin"],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":106,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0000000000000777","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]}}}